Exelixis' (EXEL) Outperform Rating Reiterated at William Blair

Key Points

• Exelixis' stock has been restated with an "outperform" rating by William Blair, while other analysts have varied target prices between $41.00 and $53.00.
• The company's recent earnings report showed a quarterly EPS of $0.75, exceeding estimates, although revenue declined 10.8% year-over-year.
• Insider trading activity has seen significant sell-offs, with executives selling hundreds of thousands of shares recently, while institutional investors hold 85.27% of the company's stock.

Exelixis (NASDAQ:EXEL - Get Free Report)'s stock had its "outperform" rating reaffirmed by analysts at William Blair in a note issued to investors on Tuesday,RTT News reports. William Blair also issued estimates for Exelixis' Q3 2025 earnings at $0.63 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.43 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.58 EPS and FY2026 earnings at $2.28 EPS.

Several other research firms have also commented on EXEL. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Morgan Stanley decreased their price objective on shares of Exelixis from $48.00 to $46.00 and set an "overweight" rating on the stock in a research report on Tuesday. HC Wainwright boosted their price objective on shares of Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Finally, Bank of America boosted their price objective on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday, June 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $44.44.

Exelixis Price Performance

Shares of NASDAQ EXEL traded up $0.08 during trading on Tuesday, hitting $36.30. 609,442 shares of the company were exchanged, compared to its average volume of 3,055,291. The company has a market cap of $9.77 billion, a price-to-earnings ratio of 17.44, a PEG ratio of 0.74 and a beta of 0.28. Exelixis has a 1 year low of $23.21 and a 1 year high of $49.62. The firm's fifty day moving average price is $43.03 and its 200 day moving average price is $38.89.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business's revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.84 EPS. On average, research analysts forecast that Exelixis will post 2.04 earnings per share for the current year.

Insider Activity at Exelixis

In other news, Director Stelios Papadopoulos sold 36,508 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $44.35, for a total transaction of $1,619,129.80. Following the completion of the transaction, the director owned 1,279,416 shares of the company's stock, valued at $56,742,099.60. This represents a 2.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Patrick J. Haley sold 126,383 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the transaction, the executive vice president directly owned 446,459 shares of the company's stock, valued at approximately $21,412,173.64. This represents a 22.06% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,605 shares of company stock worth $20,966,005. Corporate insiders own 2.82% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of EXEL. Nuveen LLC acquired a new position in shares of Exelixis during the 1st quarter valued at about $123,310,000. Invesco Ltd. increased its stake in shares of Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock valued at $132,376,000 after acquiring an additional 3,001,204 shares during the last quarter. AQR Capital Management LLC increased its position in Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company's stock worth $250,869,000 after purchasing an additional 2,926,884 shares in the last quarter. Norges Bank acquired a new stake in Exelixis during the 4th quarter worth approximately $94,867,000. Finally, Caisse DE Depot ET Placement DU Quebec increased its position in Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock worth $82,730,000 after purchasing an additional 1,907,167 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.